NEW YORK – Invivoscribe announced Thursday that its test for FLT3 mutations in patients with leukemia has achieved regulatory compliance in the UK and Switzerland.
The study, titled “Epigenetic regulation of non-canonical menin targets modulates menin inhibitor response in acute myeloid leukemia,” was recently published in Blood and focuses on acute myeloid ...
Pleco Therapeutics, a clinical-stage biopharmaceutical company developing novel therapies for difficult-to-treat cancers, ...
Two scientists describe how an acute myeloid leukemia diagnosis underscores the need for continued federal support for research and access to care.
KLAS Las Vegas on MSN6h
Friends Through It All with Intermountain HealthImagine battling cancer and discovering that the patient next to you is your longtime friend. Evelyn Ealy and Irma McCoy have ...
Title: ATNM-400 is a novel Actinium-225 antibody radioconjugate with strong efficacy in preclinical models of prostate cancer ...
Pleco Therapeutics, a clinical-stage biopharmaceutical company developing novel therapies for difficult-to-treat cancers, announces a positive ...
Company reports acceptance of an abstract at the 2025 American Society of Clinical Oncology (ASCO) conference; Continues to ...
StockNews.com started coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS – Free Report) in a report published on Wednesday. The brokerage issued a sell rating on the stock. Ayala Pharmaceuticals ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback